BRPI0819138B8 - composição, e, cartucho, conjunto ou dispositivo dispensador - Google Patents

composição, e, cartucho, conjunto ou dispositivo dispensador

Info

Publication number
BRPI0819138B8
BRPI0819138B8 BRPI0819138A BRPI0819138A BRPI0819138B8 BR PI0819138 B8 BRPI0819138 B8 BR PI0819138B8 BR PI0819138 A BRPI0819138 A BR PI0819138A BR PI0819138 A BRPI0819138 A BR PI0819138A BR PI0819138 B8 BRPI0819138 B8 BR PI0819138B8
Authority
BR
Brazil
Prior art keywords
composition
per unit
unit dose
cartridge
dispensing device
Prior art date
Application number
BRPI0819138A
Other languages
English (en)
Inventor
Peke Meijer Erwin
Groenendijk Martine
Joseph Gerardus Hendrikus Kamphuis Patrick
Johan Joseph Hageman Robert
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39591591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0819138(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of BRPI0819138B1 publication Critical patent/BRPI0819138B1/pt
Publication of BRPI0819138B8 publication Critical patent/BRPI0819138B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição, cartucho, conjunto ou dispositivo dispensador, e, uso da composição. a invenção refere-se a uma composição compreendendo (i) uridina em forma de nucleobase, nucleotídeo e/ou nucleosídeo; (ii) ácido docosaexaenóico (dha) e/ou ácido eicosapentaenóico (epa); e (iii) um tocoferol e/ou um equivalente do mesmo, sendo que referida composição apresenta: a) um peso de 200 a 3000 mg por dose unitária; b) um teor de energia inferior a 50 kcal por dose unitária; e/ou c) um volume entre 0,1 e 10 ml por dose unitária. a invenção refere-se também ao uso de referida composição na redução da carga de placa abeta e neurodegeneração, no tratamento de doenças relacionadas com funcionamento deficiente dos nervos, em particular demência, mal de alzheimer e distúrbios da memória.
BRPI0819138A 2007-11-02 2008-10-27 composição, e, cartucho, conjunto ou dispositivo dispensador BRPI0819138B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2007/050529 WO2009057994A1 (en) 2007-11-02 2007-11-02 Unit dosage for brain health
PCT/NL2008/050672 WO2009058005A2 (en) 2007-11-02 2008-10-27 Unit dosage for brain health

Publications (2)

Publication Number Publication Date
BRPI0819138B1 BRPI0819138B1 (pt) 2019-09-03
BRPI0819138B8 true BRPI0819138B8 (pt) 2021-05-25

Family

ID=39591591

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819138A BRPI0819138B8 (pt) 2007-11-02 2008-10-27 composição, e, cartucho, conjunto ou dispositivo dispensador

Country Status (9)

Country Link
US (1) US8283336B2 (pt)
EP (2) EP2537521A1 (pt)
CN (1) CN101842103A (pt)
BR (1) BRPI0819138B8 (pt)
DK (1) DK2214683T3 (pt)
ES (1) ES2430846T3 (pt)
PL (1) PL2214683T3 (pt)
PT (1) PT2214683E (pt)
WO (2) WO2009057994A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002166A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Improving memory in subjects with mini-mental state examination of 24-26
WO2011047091A1 (en) * 2009-10-13 2011-04-21 Martek Biosciences Corporation Methods for treating traumatic brain injury
JP2013507454A (ja) * 2009-10-13 2013-03-04 マーテック バイオサイエンシーズ コーポレーション 外傷性脳損傷の病理学的影響の危険を軽減する方法
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013066151A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
WO2013066153A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Composition for improving neuropsychological test battery score
WO2013066168A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Composition for improving neuropsychological test battery score
BR112014020177A8 (pt) * 2012-03-02 2021-10-19 Nutricia Nv Uso de uma composição para a fabricação de um produto para diminuir, prevenir ou reverter a conectividade cerebral funcional prejudicada e/ou organização da rede cerebral prejudicada
GB201205856D0 (en) * 2012-04-02 2012-05-16 Randall Jeremy A P Food supplement to support brain function
WO2014171813A1 (en) * 2013-04-17 2014-10-23 N.V. Nutricia Nutritional composition for improving brain function in phenylketonuria
EP3419439B1 (en) * 2016-02-22 2020-04-08 Newtricious B.V. Composition for the prevention or treatment of neurodegenerative diseases
WO2021019580A1 (en) * 2019-07-26 2021-02-04 Prosol S.P.A. Composition comprising 5'-ribonucleotides for use in the treatment of alzheimer's disease
AU2022345465A1 (en) 2021-09-17 2024-03-21 N.V. Nutricia Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2007350A6 (es) 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
AU769645B2 (en) 1987-05-29 2004-01-29 Abbott Laboratories Nourishing products enriched with nucleosides and/or nucleotides for infants and adults and processes for their preparation
AU651626B2 (en) 1990-10-24 1994-07-28 Nestec S.A. Medical foods having soluble fiber
EP0756828B2 (en) 1995-08-04 2010-09-22 N.V. Nutricia Nutritional composition containing fibres
US5792501A (en) 1996-04-15 1998-08-11 The Iams Company Queen's milk replacer
US5780081A (en) 1996-10-28 1998-07-14 Nestec S.A. Fortification of food with calcium and process of making
US6288116B1 (en) 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
US6245379B1 (en) 1998-09-30 2001-06-12 The Iams Company Method of administering a milk substitute to critical care animals
US6630452B2 (en) 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
DE10057976B4 (de) 2000-11-22 2005-02-03 Südzucker AG Mannheim/Ochsenfurt Verfahren zur Herstellung von Pektinhydrolyseprodukten
US6511696B2 (en) 2000-12-13 2003-01-28 Novartis Nutrition Ag Infant formula with free amino acids and nucleotides
HUP0400732A3 (en) * 2001-04-30 2007-05-29 Trommsdorff Arzneimittel Pharmaceutically active uridine esters
EP1634599A1 (en) 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
CA2579851C (en) 2004-09-15 2018-09-04 Massachusetts Institute Of Technology Use of uridine for improving cognitive and neurological functions
PL1888081T3 (pl) * 2005-05-23 2017-07-31 Massachusetts Institute Of Technology Kompozycje zawierające PUFA i sposoby ich zastosowania
KR20130101596A (ko) 2005-07-08 2013-09-13 마텍 바이오싸이언스스 코포레이션 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
US7829126B2 (en) * 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
EP1803358A1 (en) * 2005-12-28 2007-07-04 Laboratorios Ordesa, S.L Infant immunological formula

Also Published As

Publication number Publication date
WO2009058005A2 (en) 2009-05-07
US8283336B2 (en) 2012-10-09
BRPI0819138B1 (pt) 2019-09-03
EP2214683B1 (en) 2013-07-10
CN101842103A (zh) 2010-09-22
ES2430846T3 (es) 2013-11-22
WO2009057994A1 (en) 2009-05-07
US20100261669A1 (en) 2010-10-14
PT2214683E (pt) 2013-10-17
DK2214683T3 (da) 2013-10-21
WO2009058005A3 (en) 2009-07-16
EP2214683A2 (en) 2010-08-11
EP2214683B9 (en) 2013-12-25
PL2214683T3 (pl) 2013-12-31
EP2537521A1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
BRPI0819138B8 (pt) composição, e, cartucho, conjunto ou dispositivo dispensador
RU2014122168A (ru) Улучшение памяти у пациентов с оценкой 24-26 баллов по краткой шкале оценки психического статуса
MA33044B1 (fr) Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
CO6341563A2 (es) Compuestos organicos
PE20081150A1 (es) Inhibidores de dipetidilpeptidasa
MA33075B1 (fr) Composition destinee a la regulation du metabolism des lipides
JP2014532654A5 (pt)
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
EA202091999A2 (ru) Применение ингибиторов dpp iv
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
CO6390078A2 (es) Inihibidores de syk de imidazopirazina
RU2011115406A (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EP2037739A4 (en) POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR
PE20110711A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
BR112013031117A8 (pt) Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
UY30029A1 (es) Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
Paul et al. The potential physiological crosstalk and interrelationship between two sovereign endogenous amines, melatonin and homocysteine
GT200400068A (es) Derivados de 3-azabiciclo[3.2.1]octano
BRPI0410651A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente
GT200800235A (es) Formulacion de medicamento liquida
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
BR112016012233A8 (pt) composições compreendendo cinamaldeído, e seus usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2641 DE 17-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.